Biliary Tract Cancer Guidelines Excel at Clarity but Leave Precision Oncology Pathways Incomplete

Biliary tract cancers, a group of aggressive malignancies that includes cholangiocarcinoma and gallbladder cancer, have become a proving ground for precision oncology. Over the past decade, genomic discoveries such as FGFR2 fusions, IDH1 mutations, and high microsatellite instability have opened doors to targeted therapies once unthinkable in this hard-to-treat disease. Yet a comprehensive new systematic review suggests that the clinical practice guidelines meant to guide doctors through this genomic era are, in many cases, only half-built bridges: they tell clinicians what treatments exist, but often fail to spell out who should be tested, when, and how.

The study, led by Xiang Pan and Ziting Su of the First Affiliated Hospital of Dali University in Yunnan, China, and published in BMC Cancer, systematically evaluated clinical practice guidelines on precision oncology in biliary tract cancers using two internationally recognised appraisal instruments, AGREE II and AGREE-REX. The team searched eight databases and thirteen guideline repositories and society websites, capturing guidance published or updated between January 2016 and June 2026. From thirty individual reports, the researchers assembled twenty-seven distinct guideline families, which they then subjected to independent appraisal by three trained assessors.

What makes this analysis technically distinctive is the decision to separate two halves of the precision oncology pathway that guidelines frequently blur together: molecular testing and biomarker-directed treatment. The authors argue that precision medicine in biliary tract cancer requires more than merely listing actionable biomarkers. A complete guideline must connect the who and how of testing to the treatment or clinical trial action that follows a positive result. By applying separate AGREE-REX appraisal clusters for testing and treatment recommendations, and by mapping cross-guideline support across a prespecified twelve-topic matrix, the team created one of the most granular portraits to date of how well guidance documents serve the full genomic care pathway.

The AGREE II results reveal a striking asymmetry in guideline quality. The strongest domain was clarity of presentation, with a median score of 98.1 percent, followed by scope and purpose at 88.9 percent. In other words, when a guideline makes a recommendation, it usually states it clearly. But the infrastructure around those recommendations was consistently weaker. Patient and public involvement, methods for updating, monitoring and audit provisions, and external review all scored poorly across the field. These are the domains that determine whether a guideline remains trustworthy as evidence evolves, whether it reflects what patients actually value, and whether institutions can verify that recommendations are being followed in practice.

The AGREE-REX appraisal, which drills down to the quality of individual recommendations rather than whole documents, surfaced another weakness: values and preferences was the lowest-scoring domain in both the testing and treatment clusters. This finding suggests that guideline developers are not systematically describing the evidence underlying patient values and treatment preferences when they craft recommendations. For patients facing choices between cytotoxic chemotherapy, targeted agents, or clinical trial enrolment, that gap is more than an academic shortcoming.

On the substantive question of which biomarkers enjoy the broadest guideline support, the picture is clear. Broad molecular profiling using next-generation sequencing was supported by eighteen of twenty-seven guideline families, reflecting a growing consensus that comprehensive genomic testing, rather than single-gene assays, is the appropriate strategy in this disease. On the treatment side, the highest support went to microsatellite instability-high or mismatch repair-deficient tumours, endorsed by twenty of twenty-seven families, followed by FGFR2 alterations at seventeen and IDH1 mutations at sixteen. HER2-directed therapy was supported by twelve of twenty-six families after one unclassifiable unit was excluded. These targets map directly onto approved therapies and the antibody-drug conjugates now reshaping the treatment landscape for HER2-positive disease.

Perhaps the most consequential finding is that testing and treatment support frequently diverged. Several biomarker-treatment pairings were endorsed as therapies without corresponding guidance on molecular testing, and vice versa. A clinician reading one of these guidelines might learn that an IDH1 inhibitor is appropriate for a patient with an IDH1-mutant tumour, yet find no recommendation on how or when to test for that mutation. The authors are careful to note that such divergent coverage does not itself indicate lower recommendation quality; rather, it reveals structural incompleteness. Guidelines excel at the endpoint of the pathway while leaving the intermediate steps, the testing indications, timing, and methods, underspecified.

The review also demonstrates methodological rigour in its own appraisal process. Historical intraclass correlation coefficients across the appraisal rounds ranged from 0.918 to 0.960, indicating near-perfect agreement among the three independent assessors. A separate revision-stage sensitivity analysis incorporating de novo ratings for a subset of twenty-two families yielded a coefficient of 0.925. Sensitivity analyses that counted clinical-trial-only recommendations alongside explicit and conditional recommendations further tested the robustness of the coverage findings. The study was prospectively registered with PROSPERO under registration number CRD420261438683, and the search strategy was peer-reviewed according to the PRESS standard.

The implications for clinical practice are immediate. Biliary tract cancers are diagnosed in roughly hundreds of thousands of people worldwide each year, and outcomes remain poor, with many patients presenting at advanced stages where molecularly informed decisions carry the greatest weight. For oncologists navigating this landscape, the review functions as a meta-map: it identifies which guidelines provide the most complete testing-to-treatment pathways and where the consensus on targets such as MSI-H/dMMR, FGFR2, and IDH1 is strongest. It also flags where clinicians must supplement guideline advice, for instance by consulting molecular tumour boards or trial registries when testing guidance is absent.

For guideline developers, the authors offer a clear blueprint for the next generation of documents. Future guidance, they conclude, should explicitly link testing indication, timing, and method to post-test clinical action, while strengthening patient involvement, evidence-to-decision reporting, resource-sensitive implementation strategies, audit indicators, conflict of interest management, and prospective updating mechanisms. The finding that no external funding supported the research, with study expenses personally covered by the corresponding author, adds a note of independence to a field where commercial interests in genomic testing and targeted therapies are considerable. As precision oncology matures, the bottleneck may no longer be discovering new biomarkers but ensuring that the documents meant to translate them into bedside decisions are as rigorous, complete, and current as the science they describe.

Subject of Research: Quality appraisal of clinical practice guidelines for precision oncology in biliary tract cancers

Article Title: Quality of clinical practice guidelines on precision oncology in biliary tract cancers: a systematic review using AGREE II and AGREE-REX

Article References: Quality of clinical practice guidelines on precision oncology in biliary tract cancers: a systematic review using AGREE II and AGREE-REX. (n.d.). https://doi.org/10.1186/s12885-026-17168-8

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17168-8

Keywords: biliary tract cancer, precision oncology, clinical practice guidelines, AGREE II, AGREE-REX, cholangiocarcinoma, next-generation sequencing, FGFR2, IDH1, MSI-H/dMMR, HER2, systematic review